Study S000892

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy

ClinicalTrials.gov record

Registration

Registration: NCT01514149
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: TERMINATED
Enrollment: 73
Start: 2011-09
Primary completion: 2012-05
Lead sponsor: ConjuChem
Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:CJC-1134-PC Injection; DRUG:Weekly placebo for CJC-1134-PC Injection
Results posted: TRUE

Registered primary outcomes

Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18 [CFB to Week 18]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.